MacroGenics flips over an OS dud for cancer drug Margenza in surprising turnaround from earlier data
Cancer player MacroGenics scored a big win with its full approval for anti-HER2 drug Margenza last winter based on a head-to-head matchup with breast cancer titan Herceptin. Now, a fuller look at Margenza’s survival data months after that approval could spell a rough road ahead for the drug.
MacroGenics’ Margenza after chemo failed to significantly extend the lives of patients with advanced HER2-positive breast cancer after two or more lines of prior therapy compared with Roche’s Herceptin. Those data fly counter to the drug’s clinically meaningful progression-free survival data that won it its FDA approval back in December.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.